Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene DDR2
Variant L239R
Impact List missense
Protein Effect gain of function - predicted
Gene Variant Descriptions DDR2 L239R lies within the extracellular domain of the Ddr2 protein (UniProt.org). L239R results in transforming activity in cell culture (PMID: 22328973), and therefore, is predicted to result in a gain of Ddr2 protein function.
Associated Drug Resistance

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Transcript NM_001014796
gDNA chr1:g.162759840T>G
cDNA c.716T>G
Protein p.L239R
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_011509588 chr1:g.162759840T>G c.716T>G p.L239R RefSeq GRCh38/hg38
XM_006711344 chr1:g.162759840T>G c.716T>G p.L239R RefSeq GRCh38/hg38
XM_011509586 chr1:g.162759840T>G c.716T>G p.L239R RefSeq GRCh38/hg38
NM_001014796 chr1:g.162759840T>G c.716T>G p.L239R RefSeq GRCh38/hg38
NM_006182 chr1:g.162759840T>G c.716T>G p.L239R RefSeq GRCh38/hg38
XM_011509587 chr1:g.162759840T>G c.716T>G p.L239R RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
DDR2 L239R lung squamous cell carcinoma sensitive Dasatinib Preclinical Actionable In a preclinical study, Sprycel (dasatinib) inhibited proliferation of lung squamous cell carcinoma cells harboring a DDR2 L239R mutation in culture (PMID: 22328973). 22328973
DDR2 L239R Advanced Solid Tumor sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 L239R in culture (PMID: 22328973). 22328973
DDR2 L239R Advanced Solid Tumor sensitive Nilotinib + Saracatinib Preclinical Actionable In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 L239R in culture, with increased potency over either agent alone (PMID: 22328973). 22328973
DDR2 L239R lung squamous cell carcinoma sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited growth of lung squamous cell cancer cells harboring DDR2 L239R in culture (PMID: 22328973). 22328973
DDR2 L239R Advanced Solid Tumor sensitive Dasatinib Preclinical Actionable In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 L239R in culture (PMID: 22328973). 22328973
DDR2 L239R DDR2 T654M lung squamous cell carcinoma decreased response Dasatinib Preclinical Actionable In a preclinical study, expression of DDR2 T654M in lung squamous cell cancer cells harboring DDR2 L239R resulted in decreased sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973). 22328973
DDR2 L239R DDR2 T654I lung squamous cell carcinoma predicted - resistant Dasatinib Preclinical - Cell culture Actionable In a preclinical study, DDR2 T654I was identified as an acquired mutation in lung squamous cell carcinoma cells harboring DDR2 L239R that became resistant to Sprycel (dasatinib) in culture (PMID: 24296828). 24296828
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
DDR2 act mut lung non-small cell carcinoma sensitive Lucitanib Preclinical Actionable In a preclinical study, Lucitanib (E-3810) decreased DDR2 phosphorylation, and inhibited proliferation and induced apoptosis in lung squamous cell carcinoma cells harboring a DDR2 activating mutation in culture (PMID: 24696502). 24696502
DDR2 mutant lung squamous cell carcinoma sensitive Dasatinib Preclinical Actionable In a preclinical study, lung squamous cell cancer cells harboring DDR2 mutations demonstrated sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973). 22328973
Molecular Profile Protein Effect Treatment Approaches
DDR2 L239R gain of function - predicted DDR2 inhibitor
DDR2 L239R DDR2 T654M
DDR2 L239R DDR2 T654I